These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 28804959)

  • 1. Head-to-head comparison of prasugrel versus ticagrelor in patients undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials.
    Sakurai R; Burazor I; Bonneau HN; Kaneda H
    J Interv Cardiol; 2017 Oct; 30(5):457-464. PubMed ID: 28804959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effectiveness and safety of prasugrel and ticagrelor in patients of acute coronary syndrome undergoing percutaneous transluminal coronary angioplasty: A propensity score-matched analysis.
    Ray A; Najmi A; Khandelwal G; Jhaj R; Sadasivam B
    Indian Heart J; 2024; 76(2):133-135. PubMed ID: 38485052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Potent P2Y
    Wang C; Zhao G; Wang X; Nie S
    Biomed Res Int; 2018; 2018():8572740. PubMed ID: 30648108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of cangrelor as compared to ticagrelor in patients with ST-elevated myocardial infarction (STEMI): a systematic review and meta-analysis.
    Chakraborty S; Sarkar D; Samajdar SS; Biswas P; Mohapatra D; Halder S; Yunus M
    Egypt Heart J; 2024 Apr; 76(1):48. PubMed ID: 38625596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Prospective, Randomized, Open-Label, Blinded, Endpoint Study Exploring Platelet Response to Half-Dose Prasugrel and Ticagrelor in Patients with the Acute Coronary Syndrome: HOPE-TAILOR Study.
    Jin C; Kim MH; Bang J; Serebruany V
    Cardiology; 2017; 138(4):201-206. PubMed ID: 28810251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can prasugrel decrease the extent of periprocedural myocardial injury during elective percutaneous coronary intervention?
    Tomaniak M; Kołtowski Ł; Kochman J; Huczek Z; Rdzanek A; Pietrasik A; Gasecka A; Gajda S; Opolski G; Filipiak KJ
    Pol Arch Intern Med; 2017 Nov; 127(11):730-740. PubMed ID: 28817535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Head to head comparison of Prasugrel versus Ticagrelor in patients with acute coronary syndrome: a systematic review and meta-analysis of randomized trials.
    Bundhun PK; Shi JX; Huang F
    BMC Pharmacol Toxicol; 2017 Dec; 18(1):80. PubMed ID: 29233189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of prasugrel and ticagrelor in patients with acute coronary syndrome undergoing percutaneous coronary intervention: A meta-analysis of randomized and non-randomized studies.
    Watti H; Dahal K; Zabher HG; Katikaneni P; Modi K; Abdulbaki A
    Int J Cardiol; 2017 Dec; 249():66-72. PubMed ID: 29121759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Ticagrelor Versus Prasugrel for Inflammation, Vascular Function, and Circulating Endothelial Progenitor Cells in Diabetic Patients With Non-ST-Segment Elevation Acute Coronary Syndrome Requiring Coronary Stenting: A Prospective, Randomized, Crossover Trial.
    Jeong HS; Hong SJ; Cho SA; Kim JH; Cho JY; Lee SH; Joo HJ; Park JH; Yu CW; Lim DS
    JACC Cardiovasc Interv; 2017 Aug; 10(16):1646-1658. PubMed ID: 28838475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiplatelet treatment in diabetic patients with acute coronary syndrome undergoing percutaneous coronary intervention: a GReek AntiPlatElet registry substudy.
    Hamilos M; Petousis S; Xanthopoulou I; Goudevenos J; Kanakakis J; Sitafidis G; Vavouranakis M; Skalidis E; Kochiadakis G; Lekakis J; Vardas PE; Alexopoulos D
    Coron Artery Dis; 2018 Jan; 29(1):53-59. PubMed ID: 28834792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical impact and predictors of complete ST segment resolution after primary percutaneous coronary intervention: A subanalysis of the ATLANTIC Trial.
    Fabris E; van 't Hof A; Hamm CW; Lapostolle F; Lassen JF; Goodman SG; Ten Berg JM; Bolognese L; Cequier A; Chettibi M; Hammett CJ; Huber K; Janzon M; Merkely B; Storey RF; Zeymer U; Cantor WJ; Tsatsaris A; Kerneis M; Diallo A; Vicaut E; Montalescot G
    Eur Heart J Acute Cardiovasc Care; 2019 Apr; 8(3):208-217. PubMed ID: 28841028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of ticagrelor versus prasugrel on platelet reactivity: a meta-analysis.
    Zhang H; Zhang P; Dong P; Yang X; Wang Y; Zhang H; Yan J; Zhang Y; Zhang T; Li Y
    Coron Artery Dis; 2017 Nov; 28(7):597-604. PubMed ID: 28968313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antithrombotic potency of ticagrelor versus clopidogrel in type-2 diabetic patients with cardiovascular disease.
    Zafar MU; Baber U; Smith DA; Sartori S; Contreras J; Rey-Mendoza J; Linares-Koloffon CA; Escolar G; Mehran R; Fuster V; Badimon JJ
    Thromb Haemost; 2017 Oct; 117(10):1981-1988. PubMed ID: 28837213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ninety-Day Readmission and Long-Term Mortality in Medicare Patients (≥65 Years) Treated With Ticagrelor Versus Prasugrel After Percutaneous Coronary Intervention (from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium).
    Song C; Sukul D; Seth M; Dupree JM; Khandelwal A; Dixon SR; Wohns D; LaLonde T; Gurm HS
    Am J Cardiol; 2017 Dec; 120(11):1926-1932. PubMed ID: 29025684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of direct oral anticoagulants for stroke prevention in elderly patients with nonvalvular atrial fibrillation.
    Oertel LB; Fogerty AE
    J Am Assoc Nurse Pract; 2017 Sep; 29(9):551-561. PubMed ID: 28805310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Ticagrelor Over Time in Patients With Prior MI in PEGASUS-TIMI 54.
    Bonaca MP; Storey RF; Theroux P; Steg PG; Bhatt DL; Cohen MC; Im K; Murphy SA; Magnani G; Ophuis TO; Rudah M; Parkhomenko A; Isaza D; Kamensky G; Goudev A; Montalescot G; Jensen EC; Johanson P; Braunwald E; Sabatine MS
    J Am Coll Cardiol; 2017 Sep; 70(11):1368-1375. PubMed ID: 28882235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The PARTHENON Clinical Development Program: the Role of Ticagrelor in Patients with Atherothrombotic Disease.
    Dobesh PP; Patel M
    Cardiovasc Drugs Ther; 2017 Aug; 31(4):433-444. PubMed ID: 28866767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contemporary antiplatelet therapy in acute coronary syndromes: are there differences in outcomes and discontinuation between clopidogrel and ticagrelor?
    Harding SA; Holley A; Wilkins B; Fairley S; Simmonds M; Larsen PD
    Intern Med J; 2017 Nov; 47(11):1298-1305. PubMed ID: 28857445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic Profiles of Ticagrelor Orodispersible Tablets in Healthy Western and Japanese Subjects.
    Teng R; Hammarberg M; Carlson GF; Bokelund-Singh S; Ruderfelt T; Blychert E
    Clin Drug Investig; 2017 Nov; 37(11):1035-1045. PubMed ID: 28856602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of Antiplatelet Agents: Analysis of 'Real-World' Data from the Italian National Pharmacovigilance Network.
    Gozzo L; Navarria A; Benfatto G; Longo L; Mansueto S; Sottosanti L; Pani L; Salomone S; Drago F
    Clin Drug Investig; 2017 Nov; 37(11):1067-1081. PubMed ID: 28856572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.